Generic medicines saved the US healthcare system a record USD 254 billion in 2014, according to a new report compiled by the IMS Institute for Healthcare Informatics on behalf of the US Generic Pharmaceutical Association (GPhA).Chip Davis, President an…
Basel, October 27, 2015 – Commenting on the results, Joseph Jimenez, CEO of Novartis, said: “Novartis continued to make strong progress on innovation and key launches in the third quarter. The Pharmaceuticals and Sandoz Divisions continue to perform ex…
Princeton, New Jersey, October 16, 2015 – Sandoz today announced the US introduction of fluvastatin sodium extended-release tablets, USP, an authorized generic version (AGx) of LESCOL® XL, which is marketed by Novartis Pharmaceuticals Corporation. This…
Novartis Access is a first-of-its-kind portfolio of products aimed at increasing access to medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer in low- and low-middle-income countriesProgram supports Kenyan gover…
Holzkirchen, October 14, 2015 – Last night in Madrid, Sandoz picked-up three accolades at the Global Generics & Biosimilars Awards hosted by the Generics Bulletin including Company of the Year.The recent launch of Zarxio, the first US biosimilar, w…
Etanercept is an anti-TNF medicine used to treat a range of immunological diseases including rheumatoid arthritis and psoriasis.Sandoz is seeking approval for all indications included in the reference product’s label.Sandoz believes that the totality o…
September 29, 2015 – An estimated 17.3 million people die of cardiovascular diseases every year. That makes it the number one cause of death in the world today, with 80% of those deaths occurring in low- and middle-income countries. Ischemic heart dise…
First-of-its-kind portfolio approach in healthcare industry, aiming to increase availability and affordability of 15 medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancerNovartis portfolio to be offered to governm…
Sandoz is investing over 150 million euro and creating 100 new highly qualified jobsThe new BioInject facility will support Sandoz’s fast growing biosimilars business as well as other Novartis biologicsState-of-the-art technology will strengthen Sandoz…
Holzkirchen, September 3, 2015 – Sandoz, a Novartis company, announced today that ZarxioTM (filgrastim-sndz) is now available in the United States. Zarxio is the first biosimilar approved by the US Food and Drug Administration (FDA) and the first to la…